期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

左西孟旦治疗急性心肌梗死并心力衰竭的疗效观察 被引量：7

原文传递
导出
摘要 急性心肌梗死是急性左心衰竭的常见原因之一。心肌梗死后心脏收缩力减弱、顺应性减低、心肌收缩不协调、射血分数减低和心排血量下降导致心功能不全。
作者 尹刚 李越凡
机构地区 青岛市中心医院心内科
出处 《中国基层医药》 CAS 2012年第10期1546-1547,共2页 Chinese Journal of Primary Medicine and Pharmacy
关键词 急性心肌梗死 疗效观察 心力衰竭 左西孟旦 治疗 急性左心衰竭 心脏收缩力 心功能不全
分类号 R542.22 [医药卫生—心血管疾病]
  • 相关文献

参考文献7

  • 1无.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2010,38(8):675-690. 被引量：1978
  • 2急性心力衰竭诊断和治疗指南[J].中华心血管病杂志,2010,38(3):195-208. 被引量：836
  • 3Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure ( the LIDO study) : a randomized double-blind trial. Lancet,2002,360 (9328) : 196-202.
  • 4Moiseyev VS, P? der P,Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, Levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study ( RUSSLAN ). Eur Heart J,2002,23 ( 18 ) : 1422-1432.
  • 5Cleland JG, Ghosh J, Freemantel N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronization therapy in heart failure. Eur J Heart Fail ,2004,6 (4) :501-508.
  • 6刘爱华,王绪芳,韩桂云.脑钠肽和NT—Pro BNP检测在心力衰竭诊断中的意义[J].中国基层医药,2011,18(8):1038-1040. 被引量：35
  • 7ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute-walk test. Am J Respir Crit Care Med, 2002,166 ( 1 ) : 111- 117.

二级参考文献59

  • 1印小荣,段宝祥,何晓虹,张幼祥,李蓬.脑钠素对心功能不全的诊断价值[J].中国现代医药杂志,2005,7(6):8-11. 被引量：5
  • 2谢洪智,朱文玲.重组人脑利钠肽和硝酸甘油治疗急性失代偿性心力衰竭疗效和安全性的随机、开放、平行对照的多中心临床研究[J].中华心血管病杂志,2006,34(3):222-226. 被引量：228
  • 3中华医学会心血管病学分会 中华心血管病杂志编辑委员会.β肾上腺素能受体阻滞剂在心血管疾病应用的专家共识[J].中华心血管病杂志,2009,37:195-209.
  • 4中华医学会心血管病学分会 中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗建议.中华心血管病杂志,2007,35(12):1076-1095.
  • 5Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J, 2005, 26: 384-416.
  • 6Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 : the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC ( HFA ) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J, 2008, 29 : 2388-2442.
  • 7Hunt SA, American College of Cardiology, American Heart Association Task Force on Practice Guidelines ( Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure ). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart fa/lure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines ( Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol, 2005, 46: e1-e82.
  • 8Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Aduks: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines : developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation, 2009, 119: 1977-2016.
  • 9Liang KV, Williams AW, Greene EL, et al. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med, 2008, 36(1 Suppl) : S75-S88.
  • 10Chen D, Assad-Kottner C, Orrego C, et al. Cytokines and acute heart failure. Crit Care Med, 2008, 36(1 Suppl) : S9-S16.

共引文献2832

同被引文献43

  • 1Kivikko M, Antila S, Eha J, et al. Pharmacokinetics of levosimen- dan and its metabolites during and after a 24-hour continuous in fusion in patients with severe heart failure. Int J Clin Pharmaeol Ther,2002,40(10) :465-471.
  • 2Gheorghiade M,Teerlink JR, Mebazaa A. Pharmacology of new a- gents for the acute heart failure syndrome. Am J Cardio1,2005,96 (6) :68-73.
  • 3Ng TM. Levosimendan,a new calcium-sensitizing inotrope for heart failure. Pharmacotherapy ,2004,24 ( 10 ) : 1366-1384.
  • 4Mebazaa A, Erhardt L. Levosimendan : a new dual-action drug in the treatment of acute heart failure. Int J Clin Pract, 2003,57 (5) :410-416.
  • 5Cleland JG, Nikitin N, McGowan J. Levosimendan:first in a new class of inodilator for acute and chronic severe heart failure. Ex-pert Rev Cardiovasc Ther,2004,2( 1 ) :9-19.
  • 6Kaheinen P, Pollesello P, Levijoki J. Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiovasc Pharmaco1,2004,43 (4) :555-561.
  • 7Paraskevaidis IA, Parissis LIT, Th Kremastinos D. Anti-inflammato- ry and antiapoptotie effects of levosimendan in decompensated heart failure:a novel mechanism of drug-induced improvement in contractile performance of the failing heart. Curr Med Chem Card- iovase Hematol Agents ,2005,3 ( 3 ) :243-247.
  • 8Michaels AD, McKeown B, Kostal M, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ven- tricular wall stress, and myocardia loxygen uptake. Circulation, 2005,111 (12) : 1504-1509.
  • 9Maytin M, Colucci WS. Cardioprotection:A new paradigm in the management of acute heart failure syndromes. Am J Cardiol, 2005,96 ( Suppl ) : 26 -31.
  • 10Kyrzopoulos S, Adamopoulos S, Parissis JT, et al. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Int J Cardio1,2005,99 (3) :409-413.

引证文献7

二级引证文献71

中国基层医药
2012年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部